MBT2 Syngeneic Model Service for Bladder Cancer

The MBT2 syngeneic model is the classic FANFT-induced urothelial carcinoma platform, transplanting a carcinogen-born murine bladder tumor into syngeneic C3H/He hosts to preserve an intact immune compartment while recapitulating the drug and BCG responsiveness of human bladder cancer. Alfa Cytology delivers this model as a complete preclinical package — authenticated cell banking, subcutaneous or transurethral intravesical implantation, scheduled bioluminescence monitoring, intravesical dosing of BCG, mitomycin C, or investigational agents, and full terminal histopathology — giving sponsors a battle-tested bladder cancer system without standing up specialized catheterization and small-animal imaging teams internally.

Overview of MBT2 Syngeneic Model for Bladder Cancer

MBT-2 (mouse bladder tumor-2) is the elder statesman of murine bladder cancer models, established by Mark Soloway and colleagues in the early 1970s — with the original report appearing in Surgical Forum in 1973 — by feeding C3H/He inbred mice the nitrofuran carcinogen FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide) for 8 to 11 months until a deeply invasive, high-grade transitional cell carcinoma emerged. The line carries epithelial characteristics and, critically, shares much of the human disease's personality: a recognized association with chemical carcinogens, similar histology, weak immunogenicity, and — most importantly for translational work — parallel responses to chemotherapy and to intravesical BCG immunotherapy. That pharmacological fidelity has kept MBT-2 in continuous service for half a century, making it the historical workhorse for evaluating nearly every intravesical agent class, from mitomycin C and doxorubicin to BCG formulations, and for dissecting the immune mechanisms of bladder immunotherapy.

Fig 1. Study timeline: 2×10⁶ MBT2-luc intravesical instillation, 10–14 days to baseline, BLI on days 1/3/7/10, intravesical rBCG-dltA plus intraperitoneal anti-mPD-1, then sacrifice. (Kim, Jung Hoon, et al., 2026)

Practically, MBT-2 offers two complementary formats. Subcutaneously, the cells produce 7–10 mm tumors in syngeneic hosts within about three weeks, supporting straightforward palpation-based efficacy studies. Orthotopically, the defining protocol is transurethral catheterization followed by brief urothelial conditioning — a few microliters of silver nitrate for 15 seconds, or an acid–alkali wash — after which roughly 1 × 10⁶ cells in 100 μL PBS are instilled and retained for about two hours (in published protocols, simply until anesthesia wears off); take rates in the literature range from roughly 60% to 90%, and untreated tumors enlarge the bladder dramatically, with luciferase-tagged MBT2.Luc tumors reportedly filling more than 90% of bladder volume within two weeks. A reduced-inoculum luciferase variant — 5 × 10⁴ MBT-2-Luc cells retained for 90 minutes — supports imaging-guided randomization every ten days on IVIS-class systems, enabling quantitative readouts of intravesical BCG dose–response (including suppression of myeloid-derived suppressor cells and regulatory T cells), combination MMC/BCG strategies, dual PI3K/mTOR inhibition, and even probiotic preparations such as heat-killed Lactobacillus casei Shirota. For preclinical teams, MBT-2 thus remains the canonical system for asking bladder-cancer treatment questions in an immunocompetent, clinically faithful context.

Cell Line Information: MBT2

MBT-2 is a murine transitional cell (urothelial) carcinoma line of C3H/He origin, originally reported by Soloway et al. (Surg. Forum 24:542–544, 1973) and further characterized in 1977; it is available from the American Type Culture Collection and has been carried by intravesical bladder cancer laboratories worldwide. Luciferase- and GFP-tagged derivatives — notably MBT-2-Luc (pGL3-based, G418-selected) and the lentiviral MBT2.Luc reporter line — support noninvasive optical monitoring of orthotopic disease. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the MBT2 syngeneic model places a complete, IACUC-compliant workflow under one accountable team: authenticated, mycoplasma-free MBT-2 or reporter-tagged cell banks are maintained at low passage, syngeneic C3H/He hosts are sourced and acclimated, tumors are established by the subcutaneous route or by sterile transurethral intravesical instillation with documented take-rate performance, intravesical agents — BCG, mitomycin C, kinase inhibitors, or investigational formulations — are dosed through catheter on protocol schedules, and studies proceed through scheduled bioluminescence imaging, survival assessment, and terminal bladder histopathology, all returned as an audit-ready data package.

Workflow of MBT2 Syngeneic Model Construction

MBT-2 studies divide into rapid subcutaneous work and technically demanding intravesical modeling; both share disciplined cell preparation and the model's characteristic two-hour instillation retention. A standard program proceeds as follows.

1. Cell preparation and quality control: MBT-2 cells (or luciferase-tagged derivatives) are expanded at low passage, confirmed mycoplasma-free, and verified >95% viable by trypan blue exclusion; inocula are prepared fresh at 10⁶ cells in 100 μL PBS for intravesical use or at subcutaneous doses per protocol.
2. Host selection and acclimation: Female C3H/HeN mice, typically 8 weeks of age, are quarantined and acclimated in a specific-pathogen-free barrier facility, with studies designed around the strain's syngeneic match to the line.
3. Implantation: subcutaneous route. Cells are injected into the flank; tumors become palpable at 7–10 mm within ~20 days, enabling volume-based randomization and caliper monitoring.
4. Implantation: intravesical route. Under anesthesia with the bladder emptied by gentle expression, a 24-gauge Teflon catheter is passed transurethrally; urothelium is conditioned (e.g., ~8 μL silver nitrate for 15 seconds followed by PBS wash, or a brief HCl/NaOH cycle), and the cell suspension is instilled.
5. Retention and recovery. The instilled volume is retained for approximately two hours: practically, until anesthesia wears off — after which the catheter is removed and mice recover with analgesia and daily monitoring.
6. Engraftment confirmation and imaging: For luciferase-tagged cohorts, bioluminescence imaging after intraperitoneal D-luciferin injection confirms take and quantifies tumor burden; the reduced-inoculum variant (5 × 10⁴ cells, 90-minute retention) supports signal-based randomization with imaging every 10 days.
7. Randomization and intravesical treatment: Mice are assigned to arms by imaging signal or bladder surrogate, and intravesical agents (BCG at defined CFU doses, mitomycin C, dual PI3K/mTOR inhibitors, or investigational formulations) are instilled on protocol schedules — commonly weekly for three weeks in published designs — with body weight and clinical signs recorded.
8. Endpoint analysis and reporting: At termination, bladders are resected and weighed, tumors are scored histologically with H&E plus Ki-67, CD3, CD68, and immune-cell panels, peripheral blood MDSC and Treg populations are quantified by flow cytometry where specified, and survival data are compiled into the final report.

Fig 2. MBT2 Syngeneic Model construction workflow.

Case Study-MBT2 Syngeneic Model Development

Alfa Cytology has applied the MBT2 syngeneic platform to preclinical programs spanning intravesical BCG optimization, mitomycin C combination strategies, kinase-inhibitor instillation studies, and immune-mechanism research in bladder cancer. In these engagements, scheduled bioluminescence imaging quantified orthotopic tumor burden and treatment response in individual animals, while terminal bladder histopathology and peripheral immune profiling completed the pharmacological assessment. Study parameters — implantation route, inoculum size, retention time, instillation schedules, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

MBT-2 rewards providers who respect its history: disciplined carcinogen-line culture, sterile transurethral technique, and immunologically literate intravesical endpoints. Alfa Cytology fields all three in-house, making the MBT2 syngeneic model a dependable cornerstone for your bladder cancer program.

• Half a century of published precedent behind every protocol decision, from take-rate optimization to instillation scheduling.
• Sterile transurethral catheterization capability with conditioned-urothelium implantation at documented take rates.
• Authentic intravesical pharmacology, validated against BCG and mitomycin C reference data.
• Imaging-guided randomization using luciferase-tagged MBT-2 with serial IVIS-class quantification.
• Immune-mechanism depth, including MDSC, Treg, and tumor-infiltrate profiling by flow cytometry and immunohistochemistry.
• Both implantation formats — rapid subcutaneous screening and true orthotopic intravesical modeling — under one roof.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your bladder cancer program could benefit from the field's most seasoned syngeneic model, contact us today to discuss MBT2 study design, implantation format, instillation schedules, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.